Tim trained in London and spent time at King’s College Hospital, University College Hospital, Imperial College Healthcare and the Royal Marsden Hospital. He was awarded a Royal College of Surgeons uro-oncology fellowship at Imperial in 2009 and subsequently was the UK’s first robotic surgery fellow at Royal Marsden Hospital.
Tim subsequently worked as a locum consultant there prior to taking up his post at Southampton. His training has also included a two-year research period as a lecturer in molecular uro-pathology, which led to two masters degrees. Tim is also the founder of The Focal Therapy Clinic.
Mr Dudderidge is delighted to see men and women with all common urological conditions otherwise known as general urology. To find out more about Tim, please click here.
If you would like to book an initial consultation with Mr Tim Dudderidge you can do so by contacting the practice manager, Kirsten Dittrich:
Spire Southampton Hospital Chalybeate Cl,
Phone: 023 8076 4391
Fax: 023 80914413
EXPERT IN PROSTATE CANCER MANAGEMENT
Tim is a UK leader in prostate cancer management. He is one of only a handful of clinicians to combine an interest in imaging and precision diagnostics with skills in both focal therapy and robotic assisted laparoscopic surgery.
As one of two surgeons leading the prostate cancer service at University Hospital Southampton, he helped transform it with diagnostic pathway innovations and the development of new therapies including high intensity focused ultrasound (HIFU) and focal cryotherapy. Tim also spearheaded efforts to deliver a robotic surgery service at the Spire Southampton Hospital.
During the same period, Tim led the development of a prostate cancer research programme. This work has included evaluation of new urinary markers for cancer detection, investigation of HIFU and new imaging techniques in prostate cancer management. Tim was the principal investigator in Southampton for the landmark Prostate MRI Imaging (PROMIS) study, which confirmed the value of multi-parametric magnetic imaging in prostate cancer assessment.